etodolac has been researched along with Arthritis, Degenerative in 45 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and safety of S-etodolac with etodolac in the treatment of osteoarthritis in Indian patients." | 9.14 | A multicentric, randomized, comparative clinical trial to evaluate the efficacy and safety of S-etodolac in the treatment of osteoarthritis in Indian patients. ( Basu, I; Hardikar, M; Karne, N; Maria, A; Panse, J; Sancheti, P; Singh, S, 2010) |
| "A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10-15 mg/kg/day), for 30 days." | 9.12 | Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. ( Alva, R; Bell, L; Brooks, KC; Case, J; Conzemius, M; Drag, M; Fleishman, C; Gordon, W; Hanson, PD; Romano, D; Schuessler, J; Shelley, B; Sifferman, R, 2006) |
| "A multi-centre, double-blind, randomised parallel-group study was conducted to compare the efficacy and safety between etodolac SR and diclofenac in treating patients with osteoarthritis of the knee." | 9.10 | Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. ( Hsu, PN; Liang, TH, 2003) |
| "Etodolac (Lodine) has been marketed in the United States since 1991 for managing pain and for acute and longterm treatment of the signs and symptoms of osteoarthritis (OA)." | 9.08 | Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. ( Constantine, G; Schnitzer, TJ, 1997) |
| "The efficacy and tolerability of etodolac and indomethacin were compared in patients with osteoarthritis of the knee." | 9.07 | Double-blind, parallel comparison of etodolac and indomethacin in patients with osteoarthritis of the knee. ( Karbowski, A, 1991) |
| "In a double-blind study, the efficacy and tolerability of nimesulide 200mg/day, administered orally, was compared with etodolac 600mg/day in the treatment, for 3 months, of 200 patients suffering from osteoarthritis of the knee." | 9.07 | Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. ( Faiella, F; Friedrich, I; Lücker, PW; Magni, E; Pawlowski, C, 1994) |
| "The efficacy and tolerability of etodolac and piroxicam were compared in patients with osteoarthritis of the knee." | 9.07 | Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee. ( Astorga Paulsen, G; Baigun, S; Galvao de Figueiredo, J; Gomes de Freitas, G, 1991) |
| "The efficacy of etodolac (600 mg/day) and placebo were compared in a 4-week double-blind, parallel-group study involving 104 patients with osteoarthritis of the knee and 106 with osteoarthritis of the hip." | 9.06 | Etodolac therapy for osteoarthritis: a double-blind, placebo-controlled trial. ( Hosie, J; Scott, DL; Williams, PI, 1989) |
| "Interim results are reported for three double-blind clinical trials comparing etodolac, a new nonsteroidal anti-inflammatory drug (NSAID), with piroxicam, diclofenac, or naproxen in patients with osteoarthritis (OA) of the knee." | 9.06 | Recent clinical experience with etodolac in the treatment of osteoarthritis of the knee. ( Platt, PN, 1989) |
| "A double-blind study was carried out to compare the effectiveness and tolerability of two non-steroidal anti-inflammatory drugs, etodolac and piroxicam, in patients with osteoarthritis of the knee." | 9.06 | A double-blind comparison of etodolac and piroxicam in the treatment of osteoarthritis. ( Freitas, GG, 1990) |
| "World-wide experience with nimesulide confirms that it is an effective anti-inflammatory drug in the treatment of osteoarthritis." | 8.81 | Nimesulide, a balanced drug for the treatment of osteoarthritis. ( Huskisson, EC, 2001) |
| "The effectiveness of etodolac in the treatment of patients with osteoarthritis (OA) and with rheumatoid arthritis (RA) has been well documented in controlled clinical trials." | 8.79 | Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis. ( Veys, EM, 1994) |
| "A meta-analysis was done with the final data from three trials that provided the first results relating to efficacy and safety of the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis (OA) of the knee." | 8.78 | Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee. ( Porzio, F, 1993) |
| "To evaluate in vivo activity of carprofen, deracoxib, and etodolac on prostanoid production in several target tissues in dogs with chronic osteoarthritis." | 7.73 | In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. ( Budsberg, SC; Reynolds, LR; Sessions, JK, 2005) |
| "An open clinical trial was carried out in 57 patients with osteoarthritis of the knee, hip or spine to assess the effectiveness and tolerability of etodolac." | 7.67 | Efficacy and tolerability of etodolac in the treatment of osteoarthritis. ( Ciocci, A, 1989) |
| " Adverse reactions, mostly regarding the G-I tract, were significantly more frequent in the tenoxicam group than in the etodolac group: 23." | 6.67 | Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee. ( Bogliolo, A; Perpignano, G; Puccetti, L, 1994) |
| "To compare the efficacy and safety of S-etodolac with etodolac in the treatment of osteoarthritis in Indian patients." | 5.14 | A multicentric, randomized, comparative clinical trial to evaluate the efficacy and safety of S-etodolac in the treatment of osteoarthritis in Indian patients. ( Basu, I; Hardikar, M; Karne, N; Maria, A; Panse, J; Sancheti, P; Singh, S, 2010) |
| "A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10-15 mg/kg/day), for 30 days." | 5.12 | Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. ( Alva, R; Bell, L; Brooks, KC; Case, J; Conzemius, M; Drag, M; Fleishman, C; Gordon, W; Hanson, PD; Romano, D; Schuessler, J; Shelley, B; Sifferman, R, 2006) |
| "A multi-centre, double-blind, randomised parallel-group study was conducted to compare the efficacy and safety between etodolac SR and diclofenac in treating patients with osteoarthritis of the knee." | 5.10 | Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee. ( Hsu, PN; Liang, TH, 2003) |
| "Etodolac (Lodine) has been marketed in the United States since 1991 for managing pain and for acute and longterm treatment of the signs and symptoms of osteoarthritis (OA)." | 5.08 | Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. ( Constantine, G; Schnitzer, TJ, 1997) |
| "The efficacy and tolerability of etodolac and piroxicam were compared in patients with osteoarthritis of the knee." | 5.07 | Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee. ( Astorga Paulsen, G; Baigun, S; Galvao de Figueiredo, J; Gomes de Freitas, G, 1991) |
| "The efficacy and tolerability of etodolac and indomethacin were compared in patients with osteoarthritis of the knee." | 5.07 | Double-blind, parallel comparison of etodolac and indomethacin in patients with osteoarthritis of the knee. ( Karbowski, A, 1991) |
| "In a double-blind study, the efficacy and tolerability of nimesulide 200mg/day, administered orally, was compared with etodolac 600mg/day in the treatment, for 3 months, of 200 patients suffering from osteoarthritis of the knee." | 5.07 | Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. ( Faiella, F; Friedrich, I; Lücker, PW; Magni, E; Pawlowski, C, 1994) |
| "An on-going multi-centre, double-blind, parallel-group study is being carried out to compare the efficacy and tolerability of sustained-release (SR) formulations of etodolac and diclofenac in patients with degenerative joint disease (osteoarthritis) of the knee." | 5.07 | Double-blind comparison of etodolac SR and diclofenac SR in the treatment of patients with degenerative joint disease of the knee. ( Khan, FM; Williams, PI, 1992) |
| "The safety profile of a new sustained-release (SR) form of etodolac was evaluated in 539 young and elderly patients with osteoarthritis or rheumatoid arthritis." | 5.07 | The safety profile of sustained-release etodolac. ( Schattenkirchner, M, 1993) |
| "A double-blind study was carried out to compare the effectiveness and tolerability of two non-steroidal anti-inflammatory drugs, etodolac and piroxicam, in patients with osteoarthritis of the knee." | 5.06 | A double-blind comparison of etodolac and piroxicam in the treatment of osteoarthritis. ( Freitas, GG, 1990) |
| "Etodolac has been shown to have a favorable safety profile in short-term and long-term studies in both osteoarthritis (OA) and rheumatoid arthritis (RA)." | 5.06 | Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins. ( Russell, RI, 1990) |
| "The efficacy of etodolac (600 mg/day) and placebo were compared in a 4-week double-blind, parallel-group study involving 104 patients with osteoarthritis of the knee and 106 with osteoarthritis of the hip." | 5.06 | Etodolac therapy for osteoarthritis: a double-blind, placebo-controlled trial. ( Hosie, J; Scott, DL; Williams, PI, 1989) |
| "Interim results are reported for three double-blind clinical trials comparing etodolac, a new nonsteroidal anti-inflammatory drug (NSAID), with piroxicam, diclofenac, or naproxen in patients with osteoarthritis (OA) of the knee." | 5.06 | Recent clinical experience with etodolac in the treatment of osteoarthritis of the knee. ( Platt, PN, 1989) |
| " In this study, the effect on gastrointestinal blood loss of high-dose etodolac, 300 and 500 mg bid, versus piroxicam at its normal therapeutic dose of 20 mg qd, was investigated by the 51Cr method in 23 men with osteo- or rheumatoid arthritis." | 5.06 | Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam. ( Garg, DC; Jallad, NS; Mullane, JF; Perdomo, CS; Salom, IL; Sanda, M; Weidler, DJ, 1986) |
| "World-wide experience with nimesulide confirms that it is an effective anti-inflammatory drug in the treatment of osteoarthritis." | 4.81 | Nimesulide, a balanced drug for the treatment of osteoarthritis. ( Huskisson, EC, 2001) |
| " Clinical experience shows etodolac, 300 mg twice daily, given to elderly patients with osteoarthritis for 4 weeks, to be effective and well tolerated in this population." | 4.79 | Special considerations in the use of NSAIDs in the elderly. ( Todesco, S, 1994) |
| "The effectiveness of etodolac in the treatment of patients with osteoarthritis (OA) and with rheumatoid arthritis (RA) has been well documented in controlled clinical trials." | 4.79 | Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis. ( Veys, EM, 1994) |
| "A meta-analysis was done with the final data from three trials that provided the first results relating to efficacy and safety of the new sustained-release (SR) formulation of etodolac versus established nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis (OA) of the knee." | 4.78 | Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee. ( Porzio, F, 1993) |
| "Etodolac has previously been reported to have an excellent safety profile." | 3.76 | A global safety evaluation of etodolac. ( Karbowski, A, 1989) |
| "To evaluate in vivo activity of carprofen, deracoxib, and etodolac on prostanoid production in several target tissues in dogs with chronic osteoarthritis." | 3.73 | In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis. ( Budsberg, SC; Reynolds, LR; Sessions, JK, 2005) |
| " Data from patients 65 years and older with osteoarthritis or rheumatoid arthritis show that etodolac is as well tolerated in elderly as in younger patients." | 3.69 | Safety profile of etodolac in the elderly population. ( Bacon, PA, 1994) |
| "Etodolac is a new nonsteroidal anti-inflammatory drug (NSAID) that has shown a favorable safety profile in clinical trials in osteoarthritis (OA) and rheumatoid arthritis (RA)." | 3.68 | Global safety of etodolac: reports from worldwide postmarketing surveillance studies. ( Serni, U, 1990) |
| "An open clinical trial was carried out in 57 patients with osteoarthritis of the knee, hip or spine to assess the effectiveness and tolerability of etodolac." | 3.67 | Efficacy and tolerability of etodolac in the treatment of osteoarthritis. ( Ciocci, A, 1989) |
| "The effects of age and chronic dosing on the pharmacokinetics of the anti-inflammatory drug etodolac were evaluated in healthy young subjects, healthy elderly subjects, and elderly patients with osteoarthritis." | 3.67 | Etodolac kinetics in the elderly. ( Garg, D; Hicks, D; Kraml, M; Sanda, M; Scatina, J; Weidler, D, 1986) |
| "Etodolac is a new nonsteroidal anti-inflammatory drug (NSAID) with potent analgesic and antiarthritic properties." | 2.67 | An overview of the efficacy of etodolac in arthritic disorders. ( Bacon, PA, 1990) |
| " Adverse reactions, mostly regarding the G-I tract, were significantly more frequent in the tenoxicam group than in the etodolac group: 23." | 2.67 | Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee. ( Bogliolo, A; Perpignano, G; Puccetti, L, 1994) |
| " A total of 1276 adverse reactions (AR) were reported during the study, and fewer than half of these were related to study treatment." | 2.67 | Large-scale open trials with etodolac (Lodine) in France: an assessment of safety. ( Benhamou, CL, 1990) |
| "Aspirin was significantly more effective than placebo in only three assessments: two of the range of motion of the knee joint and one of pain while standing." | 2.65 | Etodolac, aspirin, and placebo in patients with degenerative joint disease: a twelve-week study. ( Andelman, SY, 1983) |
| " Although ketorolac, which is now available in oral form, is an effective analgesic, its long-term use is limited by a high incidence of gastrointestinal toxicity." | 2.39 | A review of selected newer nonsteroidal anti-inflammatory drugs. ( Amadio, P; Cummings, DM, 1994) |
| "Hepatic cirrhosis has no effect on the pharmacokinetics of racemic etodolac, although the effect of hepatic dysfunction on the pharmacokinetics of the individual enantiomers has yet to be determined." | 2.39 | Etodolac clinical pharmacokinetics. ( Brocks, DR; Jamali, F, 1994) |
| " The mean half-life (t1/2) was 6 to 7 hours." | 2.38 | Profile of etodolac: pharmacokinetic evaluation in special populations. ( Brater, DC; Lasseter, KC, 1989) |
| "Etodolac has also been shown to be very well tolerated." | 2.38 | A review of the antiarthritic efficacy and safety of etodolac. ( Zvaifler, N, 1989) |
| "Etodolac is a new non-steroidal agent (NSAID) with anti-inflammatory and analgesic activity." | 2.37 | Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use. ( Brogden, RN; Lynch, S, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (26.67) | 18.7374 |
| 1990's | 25 (55.56) | 18.2507 |
| 2000's | 7 (15.56) | 29.6817 |
| 2010's | 1 (2.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sancheti, P | 1 |
| Hardikar, M | 1 |
| Karne, N | 1 |
| Panse, J | 1 |
| Singh, S | 1 |
| Maria, A | 1 |
| Basu, I | 1 |
| Liang, TH | 1 |
| Hsu, PN | 1 |
| Ness, TA | 1 |
| Torres, SM | 1 |
| Kramek, EA | 1 |
| Blauvelt, MM | 1 |
| Sessions, JK | 1 |
| Reynolds, LR | 1 |
| Budsberg, SC | 2 |
| Hanson, PD | 1 |
| Brooks, KC | 1 |
| Case, J | 1 |
| Conzemius, M | 1 |
| Gordon, W | 1 |
| Schuessler, J | 1 |
| Shelley, B | 1 |
| Sifferman, R | 1 |
| Drag, M | 1 |
| Alva, R | 1 |
| Bell, L | 1 |
| Romano, D | 1 |
| Fleishman, C | 1 |
| Miyamoto, H | 1 |
| Onuma, H | 1 |
| Shigematsu, H | 1 |
| Suzuki, S | 1 |
| Sakashita, H | 1 |
| Andelman, SY | 1 |
| Perpignano, G | 1 |
| Bogliolo, A | 1 |
| Puccetti, L | 2 |
| Bacon, PA | 3 |
| Veys, EM | 1 |
| Todesco, S | 2 |
| Lücker, PW | 1 |
| Pawlowski, C | 1 |
| Friedrich, I | 1 |
| Faiella, F | 1 |
| Magni, E | 1 |
| Del Ross, T | 1 |
| Marigliano, V | 1 |
| Ariani, A | 1 |
| Brocks, DR | 1 |
| Jamali, F | 1 |
| Cummings, DM | 1 |
| Amadio, P | 1 |
| Porzio, F | 1 |
| Dreiser, RL | 1 |
| Schattenkirchner, M | 1 |
| Bacon, P | 1 |
| Schumacher, HR | 1 |
| Meng, Z | 1 |
| Sieck, M | 1 |
| Zonay, L | 1 |
| Clayburne, G | 1 |
| Baker, JF | 1 |
| Park, J | 1 |
| Baker, DG | 1 |
| Schnitzer, TJ | 1 |
| Constantine, G | 1 |
| Huskisson, EC | 1 |
| Khan, FM | 1 |
| Williams, PI | 2 |
| Karbowski, A | 2 |
| Astorga Paulsen, G | 1 |
| Baigun, S | 1 |
| Galvao de Figueiredo, J | 1 |
| Gomes de Freitas, G | 1 |
| Ciompi, ML | 1 |
| Freitas, GG | 1 |
| Russell, RI | 1 |
| Serni, U | 1 |
| Benhamou, CL | 1 |
| Brater, DC | 1 |
| Lasseter, KC | 1 |
| Zvaifler, N | 1 |
| Platt, PN | 1 |
| Hosie, J | 1 |
| Scott, DL | 1 |
| Ciocci, A | 1 |
| Gospodinoff, A | 1 |
| Fiore, L | 1 |
| Dardano, B | 1 |
| Fiore, D | 1 |
| Scapato, P | 1 |
| Scatina, J | 1 |
| Hicks, D | 1 |
| Kraml, M | 1 |
| Weidler, D | 1 |
| Garg, D | 1 |
| Sanda, M | 3 |
| Shand, DG | 1 |
| Epstein, C | 1 |
| Kinberg-Calhoun, J | 1 |
| Mullane, JF | 2 |
| Lynch, S | 1 |
| Brogden, RN | 1 |
| Jallad, NS | 1 |
| Salom, IL | 1 |
| Perdomo, CS | 1 |
| Garg, DC | 1 |
| Weidler, DJ | 1 |
11 reviews available for etodolac and Arthritis, Degenerative
| Article | Year |
|---|---|
Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Etodolac; | 1994 |
Special considerations in the use of NSAIDs in the elderly.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Digestive System; Etodolac; Female; Humans; Kidney; M | 1994 |
Etodolac clinical pharmacokinetics.
Topics: Aging; Animals; Drug Interactions; Etodolac; Humans; Intestinal Absorption; Kidney Diseases; Liver C | 1994 |
A review of selected newer nonsteroidal anti-inflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Trials as Topic; | 1994 |
Meta-analysis of three double-blind comparative trials with sustained-release etodolac in the treatment of osteoarthritis of the knee.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Delay | 1993 |
Nimesulide, a balanced drug for the treatment of osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Diclofenac; Etodolac; Humans; Nap | 2001 |
Etodolac: efficacy in osteoarthritis and effects on chondrocyte function.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cartilage; Double-Blind Method; Etodolac; Humans; Indoleace | 1990 |
Profile of etodolac: pharmacokinetic evaluation in special populations.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Etodolac; Half-Life; Hum | 1989 |
A review of the antiarthritic efficacy and safety of etodolac.
Topics: Activities of Daily Living; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Binding, | 1989 |
A global safety evaluation of etodolac.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1989 |
Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use.
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Etodolac; Humans; | 1986 |
27 trials available for etodolac and Arthritis, Degenerative
| Article | Year |
|---|---|
A multicentric, randomized, comparative clinical trial to evaluate the efficacy and safety of S-etodolac in the treatment of osteoarthritis in Indian patients.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Etodolac; Female; Humans; | 2010 |
Double-blind, randomised, comparative trial of etodolac SR versus diclofenac in the treatment of osteoarthritis of the knee.
Topics: Abdominal Pain; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase | 2003 |
Effect of dosing and sampling time on serum thyroxine, free thyroxine, and thyrotropin concentrations in dogs following multidose etodolac administration.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Drug Administration Schedule; | 2003 |
Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions.
Topics: 4-Butyrolactone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dog Diseases; Dogs; Etodolac; Fem | 2006 |
Etodolac, aspirin, and placebo in patients with degenerative joint disease: a twelve-week study.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents; Aspirin; Clinical Trials as Topic; Double-Blind Met | 1983 |
Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Delayed-Action Preparations; Di | 1994 |
Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee.
Topics: Adult; Aged; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Aspartate Aminotransfera | 1994 |
Efficacy and tolerability of etodolac in aged patients affected by degenerative joint disease (osteoarthritis) in its active phase.
Topics: Administration, Oral; Affect; Aged; Aged, 80 and over; Aging; Anti-Inflammatory Agents, Non-Steroida | 1994 |
A comparison of the efficacy of etodolac SR (Lodine SR) and etodolac (Lodine) in patients with rheumatoid arthritis or osteoarthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Dose-Response Relationship, Drug; D | 1993 |
The safety profile of sustained-release etodolac.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Dose-Response Relation | 1993 |
Worldwide experience with etodolac (Lodine) 300 mg b.i.d. in the treatment of osteoarthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Diclofenac; Double-Blind Me | 1993 |
Effect of a nonsteroidal antiinflammatory drug on synovial fluid in osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Etodolac; Humans; Interleukin-6; Knee Joint; | 1996 |
Etodolac (Lodine) in the treatment of osteoarthritis: recent studies.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Double-Blind Method; | 1997 |
Double-blind comparison of etodolac SR and diclofenac SR in the treatment of patients with degenerative joint disease of the knee.
Topics: Aged; Delayed-Action Preparations; Diclofenac; Double-Blind Method; Etodolac; Female; Hematocrit; He | 1992 |
Double-blind, parallel comparison of etodolac and indomethacin in patients with osteoarthritis of the knee.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Etodolac; Female; Humans; | 1991 |
Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Eto | 1991 |
Evaluation of the effectiveness and safety of etodolac in prolonged treatment of active osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Drug | 1991 |
An overview of the efficacy of etodolac in arthritic disorders.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; | 1990 |
A double-blind comparison of etodolac and piroxicam in the treatment of osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Etodolac; Female; Humans; | 1990 |
Endoscopic evaluation of etodolac and naproxen, and their relative effects on gastric and duodenal prostaglandins.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dinoproston | 1990 |
Etodolac: efficacy in osteoarthritis and effects on chondrocyte function.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cartilage; Double-Blind Method; Etodolac; Humans; Indoleace | 1990 |
Large-scale open trials with etodolac (Lodine) in France: an assessment of safety.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response Rel | 1990 |
Recent clinical experience with etodolac in the treatment of osteoarthritis of the knee.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinic | 1989 |
A global safety evaluation of etodolac.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Tr | 1989 |
Etodolac therapy for osteoarthritis: a double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; | 1989 |
The effect of etodolac administration on renal function in patients with arthritis.
Topics: Acetates; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Blood Urea | 1986 |
Gastrointestinal blood loss in arthritic patients receiving chronic dosing with etodolac and piroxicam.
Topics: Acetates; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Dose-Response | 1986 |
9 other studies available for etodolac and Arthritis, Degenerative
| Article | Year |
|---|---|
In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis.
Topics: Animals; Carbazoles; Cyclooxygenase Inhibitors; Dinoprostone; Dog Diseases; Dogs; Drug Administratio | 2005 |
The effect of etodolac on experimental temporomandibular joint osteoarthritis in dogs.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Remodeling; Cartilage, | 2007 |
Safety profile of etodolac in the elderly population.
Topics: Age Factors; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Delayed-Action Preparations; Dic | 1994 |
Long-term temporal evaluation of ground reaction forces during development of experimentally induced osteoarthritis in dogs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Carbazoles; Dog Diseases; | 2001 |
Etodolac.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Etodolac; Humans; Indoleac | 1991 |
Global safety of etodolac: reports from worldwide postmarketing surveillance studies.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 1990 |
Efficacy and tolerability of etodolac in the treatment of osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Etodolac; Female; Humans; Indoleacetic Acids; | 1989 |
[Open clinical study on the efficacy and tolerance of acemetacin in rheumatoid arthritis and osteoarthrosis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Etodolac; Female; Human | 1989 |
Etodolac kinetics in the elderly.
Topics: Absorption; Acetates; Administration, Oral; Adult; Aged; Aging; Blood Proteins; Chromatography, High | 1986 |